Sanam Loghavi, medical doctor from The University of Texas MD Anderson Cancer Center, discusses updates on the diagnosis, risk stratification, and treatment of lower-risk MDS. Topics include the challenges in managing LR-MDS, the importance of accurate diagnosis and risk stratification using the IPSS-M model, FDA approval of Luspattersept frontline therapy, constructing pathology reports for optimal patient care, and incorporating various diagnostic tools for diagnosing LR-MDS.

Experts Amer Zeidan and Sanam Loghavi discuss the updated ICC and WHO classifications for MDS. They explore the overlap and differences between the two systems and highlight the challenges in classifying MDS. The podcast also emphasizes the importance of a comprehensive report and the potential of AI in generating such reports. The significance of a uniform classification for MDS and its impact on clinical practice is highlighted, along with the need for improved treatments. Lastly, the podcast emphasizes the importance of providing accurate patient education resources and recognizing genetic abnormalities morphologically.